An Open-label, Multi-center, Parallel, Single Oral Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of DWP16001 in Subjects With Hepatic Impairment Compared With Subjects With Normal Hepatic Function
Latest Information Update: 10 Apr 2024
At a glance
- Drugs Enavogliflozin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Daewoong Pharmaceutical
Most Recent Events
- 05 Apr 2024 Planned End Date changed from 31 Dec 2023 to 30 Apr 2024.
- 05 Apr 2024 Planned primary completion date changed from 31 Aug 2023 to 30 Apr 2024.
- 05 Apr 2024 Status changed from not yet recruiting to recruiting.